A Multicenter, Multiple Expansion Cohort, Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Multiple Ascending Doses in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

This is a multicenter, multiple expansion cohort, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.